Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2024 San Antonio Breast Cancer Symposium
2024 ASH Annual Meeting
RSNA 2024 Annual Meeting
2024 JADPRO Live
Quantitative Imaging Workshop XXI
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
June 15, 2012
Advertisement
Advertisement
Advertisement
Dec
18
Today In Oncology
CAR T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma: ZUMA-2
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL
UICC ICCP Landmark Review of National Cancer Strategies Illuminates Progress Persistent Challenges
Researchers May Have Uncovered Protein That Helps Cancer Cells Dodge CAR T Cell Therapy
View More
Advertisement
